References
1. Herrera-Muñoz S, Buitrago-Villa C, Serna-Toro M, Restrepo-Valencia C. Arteriolopatía calcificante urémica, reporte de un caso tratado con tiosulfato de sodio. Rev. Colomb. Nefrol. 2015; 2(1):63-70. http//doi.org/10.22265/acnef.2.1.198
2. Nigwekar SU, Thadhani R, Brandenburg VM.Calciphylaxis.N Engl J Med. 2018 26;379(4):399-400. http//doi.org/10.1056/NEJMc1807324.
3. Brandenburg VM, Evenepoel P, Floege J, Goldsmith D, Kramann R, Massy Z, Mazzaferro S, et al, ERA-EDTA Working Group on CKD-MBD and EUCALNET. Lack of evidence does not justify neglect: how can we address unmet medical needs in calciphylaxis? Nephrol Dial Transplant. 2016 31(8):1211-9. http//doi.org/10.1093/ndt/gfw025.
4. el-Azhary RA, Hickson L, McBane RD. Calciphylaxis. N Engl J Med. 2018 26;379(4):397-8. http//doi.org/10.1056/NEJMc1807324
5. Maanaoui M, Provôt F, Lionet A. Calciphylaxis. N Engl J Med. 2018 26;379(4):398. http//doi.org/10.1056/NEJMc1807324.
6. Musso CG, Enz PA, Guelman R, et al. Non-ulcerating calcific uremic arteriolopathy skin lesion treated successfully with intravenous ibandronate. Perit Dial Int. 2006;26:717–718.
7. Musso CG, Enz P, Vidal F, et al. Use of sodium thiosulfate in the treatment of calciphylaxis. Saudi J Kidney Dis Transpl. 2009;20:1065–1068.
8. Musso CG, Enz P, Vidal F, Gelman R, Giuseppe LD, Bevione P, et al. Oral sodium Thiosulfate solution as a secondary preventive treatment for calciphylaxis in dialysis patients. Saudi J Kidney Dis Transplant 2008;19:820-821.
9. Zoccali C, Mallamaci F. A new treatment for calciphylaxis in hemodialysis patientes? m J Nephrol 2018;48:165-167. https://doi.org/10.1159/000491882
10. Udomkarnjananun S, Kongnatthasate K, Praditpornsilpa K et al. Treatment of calciphylaxis in CKD: A systemic review and metaanalysis. Kidney Int Rep 2019; 4:231-244. https://doi.org/10.1016/j.ekir.2018.10.002
2. Nigwekar SU, Thadhani R, Brandenburg VM.Calciphylaxis.N Engl J Med. 2018 26;379(4):399-400. http//doi.org/10.1056/NEJMc1807324.
3. Brandenburg VM, Evenepoel P, Floege J, Goldsmith D, Kramann R, Massy Z, Mazzaferro S, et al, ERA-EDTA Working Group on CKD-MBD and EUCALNET. Lack of evidence does not justify neglect: how can we address unmet medical needs in calciphylaxis? Nephrol Dial Transplant. 2016 31(8):1211-9. http//doi.org/10.1093/ndt/gfw025.
4. el-Azhary RA, Hickson L, McBane RD. Calciphylaxis. N Engl J Med. 2018 26;379(4):397-8. http//doi.org/10.1056/NEJMc1807324
5. Maanaoui M, Provôt F, Lionet A. Calciphylaxis. N Engl J Med. 2018 26;379(4):398. http//doi.org/10.1056/NEJMc1807324.
6. Musso CG, Enz PA, Guelman R, et al. Non-ulcerating calcific uremic arteriolopathy skin lesion treated successfully with intravenous ibandronate. Perit Dial Int. 2006;26:717–718.
7. Musso CG, Enz P, Vidal F, et al. Use of sodium thiosulfate in the treatment of calciphylaxis. Saudi J Kidney Dis Transpl. 2009;20:1065–1068.
8. Musso CG, Enz P, Vidal F, Gelman R, Giuseppe LD, Bevione P, et al. Oral sodium Thiosulfate solution as a secondary preventive treatment for calciphylaxis in dialysis patients. Saudi J Kidney Dis Transplant 2008;19:820-821.
9. Zoccali C, Mallamaci F. A new treatment for calciphylaxis in hemodialysis patientes? m J Nephrol 2018;48:165-167. https://doi.org/10.1159/000491882
10. Udomkarnjananun S, Kongnatthasate K, Praditpornsilpa K et al. Treatment of calciphylaxis in CKD: A systemic review and metaanalysis. Kidney Int Rep 2019; 4:231-244. https://doi.org/10.1016/j.ekir.2018.10.002
No national or foreign publication may partially or totally reproduce or translate Revista Colombiana de Nefrología articles or abstracts without prior written permission from the journal’s Editorial Board.